业聚医疗公布上市后首份全年业绩,收入创新高达1.37亿美元,经调整净利润升25%至约26.7百万美元 OrbusNeich Medical Group Holdings Limited Mar 08, 2023 18:02 HKT/SGT Read More
業聚醫療公佈上市後首份全年業績,收入創新高達1.37億美元,經調整淨利潤升25%至約26.7百萬美元 OrbusNeich Medical Group Holdings Limited Mar 08, 2023 18:01 HKT/SGT Read More
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million OrbusNeich Medical Group Holdings Limited Mar 08, 2023 18:00 HKT/SGT Read More
隨著美國衛生系統面臨越來越大的填補人員空缺的壓力,CGFNS 聯盟發布了外國衛生工作者道德招聘的更新標準 CGFNS International Mar 07, 2023 13:30 HKT/SGT Read More
With U.S. Health Systems Under Growing Pressure to Fill Staff Vacancies, CGFNS Alliance Releases Updated Standards for Ethical Recruitment of Foreign Health Workers CGFNS International Mar 07, 2023 13:30 HKT/SGT Read More
随着美国卫生系统面临越来越大的填补人员空缺的压力,CGFNS 联盟发布了外国卫生工作者道德招聘的更新标准 CGFNS International Mar 07, 2023 13:30 HKT/SGT Read More
EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong EC Healthcare Mar 06, 2023 15:50 HKT/SGT Read More
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請(sBLA)が米国FDAに受理され、優先審査に指定 Eisai Mar 06, 2023 10:00 JST Read More
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Mar 06, 2023 09:58 HKT/SGT Read More
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology Prenetics Global Limited Mar 04, 2023 15:40 HKT/SGT Read More
CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022 Aoxin Q&M Dental Group Ltd Mar 03, 2023 08:00 HKT/SGT Read More
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan Eisai Mar 02, 2023 09:45 HKT/SGT Read More
Q&M reports lower full year profits due to impairments and decrease in Covid-19 related revenue Q&M Dental Group Ltd Mar 01, 2023 23:00 HKT/SGT Read More
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration Eisai Feb 28, 2023 14:28 HKT/SGT Read More